(0.32%) 5 116.45 points
(0.31%) 38 359 points
(0.35%) 15 984 points
(-0.89%) $83.10
(5.93%) $2.04
(0.38%) $2 356.20
(0.42%) $27.65
(3.93%) $958.35
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.96%
@ $16.78
発行日: 15 2月 2024 @ 01:57
リターン: -1.55%
前回のシグナル: 2月 14 - 05:50
前回のシグナル:
リターン: 3.13 %
Live Chart Being Loaded With Signals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease...
Stats | |
---|---|
本日の出来高 | 74 677.00 |
平均出来高 | 750 419 |
時価総額 | 809.36M |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-1.280 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.74 |
ATR14 | $0.0330 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Mills Kenneth T. | Buy | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Stock Options (Right to Buy) |
2024-03-19 | Vasista Vittal | Buy | 20 041 | Common Stock |
2024-03-19 | Vasista Vittal | Sell | 20 041 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
56.21 |
Last 99 transactions |
Buy: 2 306 609 | Sell: 467 606 |
ボリューム 相関
Regenxbio Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Regenxbio Inc 相関 - 通貨/商品
Regenxbio Inc 財務諸表
Annual | 2023 |
収益: | $90.24M |
総利益: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2023 |
収益: | $90.24M |
総利益: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2022 |
収益: | $112.72M |
総利益: | $58.18M (51.61 %) |
EPS: | $-6.50 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $3.01 |
Financial Reports:
No articles found.
Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。